Board Meeting2 Nov 2026, 08:00 pm
Eiko Lifesciences Board Meeting on Nov 5 to Approve Q2 FY27 Results
AI Summary
Eiko Lifesciences Ltd has announced that its Board of Directors will convene on November 5, 2026, to approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2026. The trading window for designated persons and their immediate relatives will remain closed until 48 hours after the declaration of these results, in accordance with SEBI regulations.
Key Highlights
- Board meeting scheduled for November 5, 2026.
- To approve Unaudited Standalone and Consolidated Financial Results.
- Results pertain to the quarter and half-year ended September 30, 2026.
- Trading window closure for designated persons extended.
Price Impact
More from EIKO